Skip to content

Active substances

Simvastatin

Author: Markus Falkenstätter, BScReviewed by Mag. pharm. Stefanie Brandauer (Pharmacist)
Contents
  1. Basics
  2. Pharmacology
  3. Toxicity

Advertisement

Basics

Simvastatin belongs to the class of drugs called lipid-lowering agents and statins. Simvastatin is used to lower cholesterol levels in the blood. Too high cholesterol levels (mainly LDL cholesterol) can lead to atherosclerotic diseases such as coronary heart disease or myocardial infarctions.

Simvastatin requires a prescription and is administered in tablet form.

Pharmacology

Pharmacodynamics

The effect of simvastatin results from inhibition of the enzyme HMG-CoA reductase. This enzyme is significantly involved in the synthesis of cholesterol in the liver. The inhibition therefore results in an overall lower cholesterol level in the blood. Indirectly, the reduced synthesis also increases the number of receptors for LDL cholesterol in the body's cells, as a result of which LDL cholesterol in particular is more readily absorbed from the blood into the cells.

Pharmacokinetics

The oral bioavailability of simvastatin is only about 5%. However, this value is irrelevant in the case of simvastatin, since the drug's site of action is the liver. Thus, 100% of the given dose reaches the desired target. The highest plasma concentration is reached after about 1.5-2.5 hours. Approximately 95% of the substance is bound in the blood. The majority of the substance is broken down in the liver via the CYP3A4 and CYP3A5 enzymes and excreted in the urine (40%) and stool (60%). The elimination half-life is approximately 4 hours.

Drug interactions

All drugs interacting with CYP3A4 may lead to increased plasma levels of simvastatin, resulting in serious side effects.

Toxicity

Side effects

Typical side effects include:

  • Upper abdominal discomfort
  • transaminase increase (liver enzymes)
  • myopathies (muscle damage)

These side effects occur rarely and are most common when there is an overdose or interaction with other drugs.

Toxicological data

LD50 (rat, oral): 4438 mg-kg-1

Markus Falkenstätter, BSc

Author

Markus Falkenstätter, BSc

Pharmacy student

Markus Falkenstätter is a writer on pharmaceutical topics in Medikamio's medical editorial team. He is in the last semester of his pharmacy studies at the University of Vienna and loves scientific work in the field of natural sciences.

Mag. pharm. Stefanie Brandauer

Reviewer

Mag. pharm. Stefanie Brandauer

Pharmacist

Stefanie Lehenauer has been a freelance writer for Medikamio since 2020 and studied pharmacy at the University of Vienna. She works as a pharmacist in Vienna and her passion is herbal medicines and their effects.


Editorial principles

All information used for our content comes from verified sources (recognised institutions, specialists, studies by renowned universities). We place great value on the qualification of the authors and the scientific background of the information, so that our research is based on scientific evidence.